Secondary outcome: acceptability of treatment · people with Alzheimer's disease
Donepezil 23 mg/day probably leads to higher acceptability of treatment (as measured by withdrawals from trial… compared with donepezil 10 mg/day (moderate certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · people with Alzheimer's disease
Donepezil 23 mg/day probably leads to higher incidence of adverse events (at least one adverse event by 24 weeks) compared with donepezil 10 mg/day (moderate certainty).
1 finding from 1 review
Change in ADAS‐Cog · people with Alzheimer's disease
1 finding from 1 review
Change in MMSE · people with Alzheimer's disease
1 finding from 1 review
Clinician‐rated global impression test (improved compared with baseline assessed using CIBIC‐plus at 24 weeks) · people with Alzheimer's disease
Donepezil 10 mg/day showed no clear difference in clinician‐rated global impression test (improved compared with… compared with donepezil 5 mg/day (moderate certainty).
1 finding from 1 review
Secondary outcome: acceptability of treatment · people with Alzheimer's disease
Donepezil 10 mg/day probably leads to higher acceptability of treatment (as measured by withdrawals from trial… compared with donepezil 5 mg/day (moderate certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · people with Alzheimer's disease
Donepezil 10 mg/day probably leads to higher incidence of adverse events (at least one adverse event by 24 weeks) compared with donepezil 5 mg/day (moderate certainty).
1 finding from 1 review
Cognitive function · people with Alzheimer's disease
1 finding from 1 review
Persistent bacteriuria · children with lower urinary tract infection
It is very uncertain whether 10‐day trimethoprim changes persistent bacteriuria compared with 10‐day trimethoprim+sulfamethoxazole (very low certainty).
1 finding from 1 review
Persistent symptoms · children with lower urinary tract infection
It is very uncertain whether 10‐day trimethoprim changes persistent symptoms compared with 10‐day trimethoprim+sulfamethoxazole (very low certainty).
1 finding from 1 review
Recurrence · children with lower urinary tract infection
It is very uncertain whether 10‐day trimethoprim changes recurrence compared with 10‐day trimethoprim+sulfamethoxazole (very low certainty).
1 finding from 1 review
Serious adverse events · People with P. vivax malaria1
1 finding from 1 review
Other adverse events · People with P. vivax malaria1
1 finding from 1 review
Short term mortality · patients with laparoscopic cholecystectomy.
1 finding from 1 review
Serious adverse events · patients with laparoscopic cholecystectomy.
It is very uncertain whether day‐surgery changes serious adverse events compared with overnight stay surgery (very low certainty).
1 finding from 1 review
Quality of life · patients with laparoscopic cholecystectomy.
It is very uncertain whether day‐surgery changes quality of life compared with overnight stay surgery (very low certainty).
1 finding from 1 review
Pain · patients with laparoscopic cholecystectomy.
1 finding from 1 review
Return to normal activities (days) · patients with laparoscopic cholecystectomy.
1 finding from 1 review
Patient readmissions · patients with laparoscopic cholecystectomy.
It is very uncertain whether day‐surgery changes number of hospital readmissions compared with overnight stay surgery (very low certainty).
1 finding from 1 review
Failed discharge · patients with laparoscopic cholecystectomy.
It is very uncertain whether day‐surgery changes failed discharge compared with overnight stay surgery (very low certainty).
1 finding from 1 review